Development of the 2nd generation neurokinin-1 receptor antagonist LY686017 for social anxiety disorder

European Neuropsychopharmacology

Volumn 20, Issue 2, 2010, Pages 80-87

  Tauscher, Johannes ^a   Kielbasa, William ^a   Iyengar, Smriti ^a   Vandenhende, Francois ^a   Peng, Xiaomei ^a   Mozley, David ^a   Gehlert, Donald R ^a   Marek, Gerard ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

Neurokinin 1 receptors; Positron emission tomography; Randomized clinical trial; Social anxiety disorder; Substance P

Indexed keywords

BRAIN RECEPTOR; LY 686017; NEUROKININ 2 RECEPTOR ANTAGONIST; PAROXETINE; PLACEBO; SUBSTANCE P; UNCLASSIFIED DRUG;

ADULT; ANIMAL EXPERIMENT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG ELIMINATION; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; HUMAN; IMAGE ANALYSIS; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NONHUMAN; OUTCOME ASSESSMENT; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN LOCALIZATION; PSYCHOLOGICAL RATING SCALE; RANDOMIZED CONTROLLED TRIAL; SOCIAL PHOBIA; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT;

ADULT; ANIMALS; ANTI-ANXIETY AGENTS; ANXIETY DISORDERS; BRAIN; DOSE-RESPONSE RELATIONSHIP, DRUG; GERBILLINAE; HUMANS; MALE; PAROXETINE; PEPTIDE FRAGMENTS; PYRIDINES; RADIOLIGAND ASSAY; RECEPTORS, NEUROKININ-1; STEREOTYPED BEHAVIOR; SUBSTANCE P; TREATMENT OUTCOME; TRIAZOLES;

EID: 73249132746     PISSN: 0924977X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.euroneuro.2009.10.005     Document Type: Article

References (21)

1. Bayes M., Rabasseda X., and Prous J.R. Gateways to clinical trials. Methods Find Exp. Clin. Pharmacol. 27 (2005) 331-372
2. Bergstrom M., Fasth K.J., Kilpatrick G., Ward P., Cable K.M., Wipperman M.D., Sutherland D.R., and Langstrom B. Brain uptake and receptor binding of two [11C]labelled selective high affinity NK1-antagonists, GR203040 and GR205171-PET studies in rhesus monkey. Neuropharmacology 39 (2000) 664-670
3. 11C]GR205171. In: Senda M., Kimura Y., and Herscovitch P. (Eds). Brain Imaging Using PET (2002), Academic Press, San Diego, CA
4. Blanco C., Schneier F.R., Schmidt A., Blanco-Jerez C.R., Marshall R.D., Sanchez-Lacay A., and Liebowitz M.R. Pharmacological treatment of social anxiety disorder: a meta-analysis. Depress. Anxiety 18 (2003) 29-40
5. Chernet E., Martin L.J., Li D., Need A.B., Barth V.N., Rash K.S., and Phebus L.A. Use of LC/MS to assess brain tracer distribution in preclinical, in vivo receptor occupancy studies: dopamine D2, serotonin 2A and NK-1 receptors as examples. Life Sci. 78 (2005) 340-346
6. Ebner K., Muigg P., Singewald G., and Singewald N. Substance P in stress and anxiety: NK-1 receptor antagonism interacts with key brain areas of the stress circuitry. Ann. N. Y. Acad. Sci. 1144 (2008) 61-73
7. Furmark T., Appel L., Michelgard A., Wahlstedt K., Ahs F., Zancan S., Jacobsson E., Flyckt K., Grohp M., Bergstrom M., Pich E.M., Nilsson L.G., Bani M., Langstrom B., and Fredrikson M. Cerebral blood flow changes after treatment of social phobia with the neurokinin-1 antagonist GR205171, citalopram, or placebo. Biol. Psychiatry 58 (2005) 132-142
8. Gardner C.J., Armour D.R., Beattie D.T., Gale J.D., Hawcock A.B., Kilpatrick G.J., Twissell D.J., and Ward P. GR205171: a novel antagonist with high affinity for the tachykinin NK1 receptor, and potent broad-spectrum anti-emetic activity. Regul. Pept. 65 (1996) 45-53
9. Guy W. ECDEU Assessment Manual for Psychopharmacology - Revised (DHEW Publ No ADM 76-338) (1976), U.S. Department of Health, Education, and Welfare, Public Health Service, Alcohol, Drug Abuse, and Mental Health Administration, NIMH Psychopharmacology Research Branch, Division of Extramural Research Programs, Rockville, MD
10. Hamilton M. The assessment of anxiety states by rating. Br. J. Med. Psychol. 32 (1959) 50-55
11. Keller M., Montgomery S., Ball W., Morrison M., Snavely D., Liu G., Hargreaves R., Hietala J., Lines C., Beebe K., and Reines S. Lack of efficacy of the substance p (neurokinin1 receptor) antagonist aprepitant in the treatment of major depressive disorder. Biol. Psychiatry 59 (2006) 216-223
12. Kramer M.S., Cutler N., Feighner J., Shrivastava R., Carman J., Sramek J.J., Reines S.A., Liu G., Snavely D., Wyatt-knowles E., Hale J.J., Mills S.G., Maccoss M., Swain C.J., Harrison T., Hill R.G., Hefti F., Scolnick E.M., Cascieri M.A., Chicchi G.G., Sadowski S., Williams A.R., Hewson L., Smith D., Carlson E.J., Hargreaves R.J., and Rupniak N.M. Distinct mechanism for antidepressant activity by blockade of central substance P receptors. Science 281 (1998) 1640-1645
13. Kramer M.S., Winokur A., Kelsey J., Preskorn S.H., Rothschild A.J., Snavely D., Ghosh K., Ball W.A., Reines S.A., Munjack D., Apter J.T., Cunningham L., Kling M., Bari M., Getson A., and Lee Y. Demonstration of the efficacy and safety of a novel substance P (NK1) receptor antagonist in major depression. Neuropsychopharmacology 29 (2004) 385-392
14. Liebowitz M.R. Social phobia. Mod. Probl. Pharmacopsychiatry 22 (1987) 141-173
15. Patlak C.S., and Blasberg R.G. Graphical evaluation of blood-to-brain transfer constants from multiple-time uptake data. Generalizations. J. Cereb. Blood Flow Metab. 5 (1985) 584-590
16. Patlak C.S., Blasberg R.G., and Fenstermacher J.D. Graphical evaluation of blood-to-brain transfer constants from multiple-time uptake data. J. Cereb. Blood Flow Metab. 3 (1983) 1-7
17. Robb R.A., and Barillot C. Interactive display and analysis of 3-D medical images. IEEE Trans. Med. Imag. 8 (1989) 217-226
18. Robb R.A., Hanson D.P., Karwoski R.A., Larson A.G., Workman E.L., and Stacy M.C. Analyze: a comprehensive, operator-interactive software package for multidimensional medical image display and analysis. Comput. Med. Imaging Graph. 13 (1989) 433-454
19. Sheehan D.V. Sheehan Disability Scale. 2000. Handbook of Psychiatric Measures. American Psychiatric Association. Task Force for the Handbook of Psychiatric Measures (1983), American Psychiatric Association, Washington, DC
20. Sheehan D.V., Lecrubier Y., Sheehan K.H., Amorim P., Janavs J., Weiller E., Hergueta T., Baker R., and Dunbar G.C. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for Dsm-Iv and Icd-10. J. Clin. Psychiatry 59 Suppl 20 (1998) 22-33
21. Zamuner S., Gomeni R., and Bye A. Estimate the time varying brain receptor occupancy in PET imaging experiments using non-linear fixed and mixed effect modeling approach. Nucl. Med. Biol. 29 (2002) 115-123